Future cancer research priorities in the USA: a Lancet Oncology Commission.
Futreal A, Gupta S, Anderson KC, Coit DG, Garraway L, Hughes-Halbert C, Raghavan D, Butte AJ, Naredi P, Sullivan R, Mitchell B, Pomper MG, Meropol NJ, Ritchie C, Jaffee EM, Agus DB, Le QT, Alexander BM, Bhatia S, Frazier AL, Heath J, Peppercorn J, Wolchok JD, Ashworth A, Draetta G, Gambhir SS, Dang CV, Bluestone JA, Kittles R, Ornish D, Ibrahim R, Mayer DK, McMasters K, Wong SL, Jadvar H, Hudis C, Lippman SM, Mardis ER, Mankoff D, Davis M, DePinho RA, Yung A, Diasio RB, Wahl R, Barker AD, Davidson NE, Ganz PA, Gerson S, Schwarz SW, Bastani R, Brawley O, Hoffman RI, Kavanagh B, Pawlik TM
Lancet Oncol 18 e653-e706 11/01/2017
We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.